🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against superbug strains of the infection, according to scientists.

An International Public Health Issue

The sexually transmitted infection are escalating globally, with data suggesting in excess of 82 million instances per year. Especially elevated rates are reported in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the face of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance showed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is employed against urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This milestone marks a huge turning point in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Results and Global Access

According to results published in a major medical journal, zoliflodacin successfully treated the vast majority of uncomplicated infections. This places it at an comparable level with the current standard treatment, which combines a dual-drug approach. The trial enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Medical professionals treating patients have expressed hope. Access to a one-pill regimen such as this is seen as a "critical tool" for managing the epidemic. This is viewed as essential to reduce the burden of the illness for individuals and to halt the transmission of untreatable gonorrhoea around the world.